Excipient-Control Strategies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Excipient-Control Strategies
The authors outline excipient-control strategies and practices for the manufacture, distribution, and receipt of excipients.


Pharmaceutical Technology


Looking forward

By following the measures described in this article, the excipient supply chain can continue to provide excipients that are suitable for use in pharmaceuticals.

Irwin Silverstein*, PhD, is vice-president and chief operating officer, and Arthur Falk, PhD, is president and CEO, both at International Pharmaceutical Excipients Auditing,1655 N. Fort Myer Drive, Suite 700, Arlington, VA 22209, tel. 703.351.5266,
. Dale Carter, MS, is global director of quality of J.M. Huber's silica business unit. Maria Guazzaroni Jacobs, PhD, is director of quality and regulatory policy for worldwide pharmaceutical sciences at Pfizer. David Schoneker is director of global regulatory affairs at Colorcon, chairman of the International Pharmaceutical Excipients Council of the Americas (IPEC–Americas), and a member of Pharmaceutical Technology's Editorial Advisory Board.

*To whom all correspondence should be addressed.

References

1. Code of Federal Regulations, Title 21 Food and Drugs (US Government Printing Office, Washington, DC) Part 110, pp. 216–226.

2. IPEC, "White Paper on Excipient Pedigree," manuscript in progress as of Sept. 3, 2008.

3. IPEC–Americas, Standardized Excipient Information Protocol User Guide (Arlington, VA, 2005).

4. D. Klug, A. Van Meter, and Laura Horne, "The Excipient Information Package, A Win–Win Solution," Pharm. Technol. 31 (11), 121–122 (2007).

5. USP 31–NF 26 General Chapter <1078>, "Good Manufacturing Practices for Excipients."

6. IPEC, The Joint IPEC–PQG Good Manufacturing Practices Guide for Bulk Excipients (2006).

7. IPEC, The Joint IPEC–PQG Good Manufacturing Practices Audit Guide for Pharmaceutical Excipients (2007).

8. IPEC, The IPEC Good Distribution Practices Guide for Pharmaceutical Excipients (2006).

9. IPEC, The IPEC Good Distribution Practices Guide for Pharmaceutical Excipients (2008).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here